EP3544676A1 - Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebe - Google Patents
Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebeInfo
- Publication number
- EP3544676A1 EP3544676A1 EP17751656.4A EP17751656A EP3544676A1 EP 3544676 A1 EP3544676 A1 EP 3544676A1 EP 17751656 A EP17751656 A EP 17751656A EP 3544676 A1 EP3544676 A1 EP 3544676A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pulses
- main
- amplitude
- pulse
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
Definitions
- the invention relates to a device for influencing biological processes in a living tissue, in particular a human body, for acting on at least part of the tissue with a pulsating magnetic field.
- the invention relates to a device and an electrical or electromagnetic signal for influencing biological processes in a living tissue, in particular a human body, by applying at least part of the tissue to a pulsating electromagnetic field.
- the sinusoidal magnetic fields used in semi-invasive pulsed magnetic field techniques had a frequency of 2 to 20 Hz and magnetic flux densities between 1 mT and 10 mT.
- An alternating voltage for generating an external magnetic field was induced on implanted electrodes with the aid of a so-called secondary element.
- noninvasive treatment without a secondary element was also known in which only very weak electrical currents were induced in the treated part of the body which was located in the center of the coil. Also devices for whole body therapy have been known since the 70s, in which the field lines are distributed evenly throughout the body.
- a generator is used to drive a magnetic field generating device, in which the generator controls the magnetic field generating device in such a way that the magnetic field consists of a plurality of magnetic fields consists of their temporal distance and amplitude course characteristically shaped fundamental pulses or main pulses.
- the pulse frequency is usually between 0 and 1000 Hz.
- Such a main pulse can be sinusoidal, trapezoidal or sawtooth (EP 0 594 655 B1 (König Herbert), EP 0 729 318 B1 (Fischer Gerhard, EP-A-0 377 284)).
- EP 0 995 463 B1 (Kafka Wolf A) have an average exponentially increasing sinusoidally modulated field intensity profile with magnetic flux densities in the range from nanoTesla to several milliTesla differ in their amplitudes and / or rise or fall slopes, ultimately thus also in their individual duration (see EP 0 995 463 B1).
- the magnetic fields are frequently generated by one or more electrical coils which are also controlled independently of one another (EP 1 364 679 A2, EP-A 0 266 807, EP-A-0 266 907, DE-A 4 221 739, US-A-5 181 902, WO-A-96/32159, UA-A-4 428 366, EP 0 995 463 B1).
- the therapeutic application is usually noninvasive for operational reasons and the associated risks.
- the influence of the biological system is based on a still unknown interaction of energy components of the magnetic and electrical field components generated by the devices.
- the physiological and biological interactions triggered by the applied electric and magnetic field are then energetically activated to activate the reactivity of molecular structures involved in the naturally-occurring and self-sustaining regulatory mechanisms.
- the energetic activation can be triggered directly, by magnetic or / and by the principle of induction (Maxwell's equations) and indirectly, by electrical force effects.
- the molecular structures can have ionic, atomic and molecular forms.
- EP 0 995 463 B1 describes that an electromagnetic field leads to a significant activation of a number of differentiated physiological-physiological processes compared to unbound biological objects. For example, from
- the distribution of the amplitudes, the configuration of the edge slopes and the superposition of the sub-pulses is therefore of crucial importance, since these parameters characterize the intensity distribution over time.
- the temporal field intensity distributions therefore have a similar importance to the structure-activity relationship of pharmaceutical active ingredients in pharmacy.
- the intensity profile over time has been adapted so that the pulses are more finely adjusted to the requirements of the therapy.
- the optimal shape and sequence of the subpulses is individually very different. It depends on the type of tissue applied by the field, on the desired healing success and on the individual. A crucial factor in the stimulation of exchange processes in the Body tissue probably has the high, due to the large number of superimposed sub-pulses proportion of the rising or falling flank sections.
- the object of the invention is to provide over the prior art, an improved device and an improved electrical or electromagnetic signal with which a faster and in their physiological effect broader influence, in particular stimulation, biological processes is made possible by a wide band of electromagnetic activatable molecular structures is addressed and thus a broader physiological range of action is guaranteed.
- the invention is directed to the broadest possible energetic support of the complex cross-linked molecular regulatory processes.
- the accompanying therapy concept is therefore preventative and focused on regeneration, maintenance and well-being.
- a device comprising a pulse generator and a field generating device for generating a pulsating electromagnetic field.
- the pulse generator is used to control the field generating device, wherein the pulse generator controls the field generating device via suitable current-voltage sequences so that the pulsating electric or electromagnetic field consists of a plurality of, with respect to their temporal amplitude characteristic shaped individual pulses whose frequency is between 1 and 1000 Hz ,
- Such a single pulse can be built up from a superimposition of a basic pulse rising or falling according to a power function with a series of applied pulses of shorter duration and different shape and time sequence.
- y (x) magnetic field amplitude within a main pulse as a function of x
- x the time course
- a a parameter for adjusting the temporal amplitude curve of each main pulse (envelope curve)
- b the number of sub-pulses
- k a factor for adjusting the amplitude of the sub-pulses
- the parameter a is in a range from 0.1 to 50, preferably in a range from 0.5 to 10 and particularly preferably in a range from 1 to 5.
- the parameter b is in this case in a range from 0.5 to 50 , preferably in a range of 1 to 10, and more preferably in a range of 2 to 5.
- the above-mentioned function (1) is understood as a function which is suitable for describing a corresponding course of amplitude, but describes the amplitude progression with respect to the illustrated function by means of other functions or functional components. These are in particular those functions which contain trigonometric functions such as sin x, cos x, aresin x or arecos x. These functions or subfunctions can replace individual components of the formula.
- the device is in this case designed such that the sub-pulses generated by it are superimposed by secondary pulses. According to the invention, these secondary pulses have a phase shift ⁇ relative to the sub-pulses which is -0.5 ⁇ ⁇ 0.5 and where the phase shift ⁇ is not equal to 0.
- the amount of phase shift ⁇ is greater than 0.1, in a particularly preferred embodiment, the amount of phase shift ⁇ is greater than 0.25.
- the pulses generated by the device according to the invention with the additional secondary pulses lead to a much faster excitation of metabolic processes in the tissue acted upon. This could be due to the fact that the pulses superimposed on the fundamental pulses improve the physiological exchange processes via intracorporeal membrane systems, since the additional pulses according to the law of induction (Maxwell's equations) are more specific in accordance with the special sequence of individual pulses induce electromagnetic field peaks which, for example via the electromotive force effects emanating from them, respond to the generally highly selective physicochemical reaction mechanisms by a corresponding broadband lowering of the activation energies and thus stimulate the physiological exchange processes, above all in membrane regions. This stimulation leads in particular to an increased 02 utilization.
- a particular advantage of the present invention and of the electrical or electromagnetic pulses generated by it is that excitation of the metabolic processes can be detected even in the case of only local exposure to living tissue even in the unoccupied regions of the tissue.
- the membranes of the membrane systems are influenced directly or by the potentials formed in the collagen, or only by a change in the microenvironment of the cell.
- This mechanism is based on electrochemical transfer, which modifies cell activity by shifting the ionic atmosphere in the extracellular space and thus in the intracellular space.
- the main reason for this is the capacitive charging of the cell membrane by the electrical component of the pulsating electromagnetic fields.
- the permeability change which is possible due to the structural and charge displacement in the membrane, in particular in the area of the pores, influences the passive ion transport and diffusion processes.
- the close coupling of surface reaction and transmembrane transport means that above all active transport systems, such as the Na-K pump, represent an important starting point for the induced energy.
- a device which comprises a pulse generator and a field generating device for generating an electromagnetic field.
- the pulse generator is used to control the field generating device, wherein the pulse generator, the field generating device via suitable current or voltage sequences so controls that the pulsating magnetic field from a Set of individually adjustable individual pulses and a plurality of finely graded in terms of the sequence of individual pulses main and secondary pulses in such a way that the spectral composition reaches the highest possible energy density.
- Such an individual pulse may be composed of an amplitude sequence, which varies in its mean in terms of its amplitude or in the manner of a power function, on the average or in descending order of successive main and secondary pulses in its sequence of individual pulses. Characterized by the connecting lines of the extrema (envelopes) of the individual main pulses, the resulting pulses themselves can assume a pulse-shaped course depending on the selected conditions.
- y n (x) magnetic field amplitude within a secondary pulse as a function of x
- x the time course; where x starts again for each side pulse with the same initial value
- a n a parameter for adjusting the temporal amplitude curve of each secondary pulse
- b n the number of secondary sub-pulses
- k n a factor for adjusting the amplitude of the sub-sub pulses with a n , b n , c n 0.
- the parameter a is in a range from 0.1 to 50, preferably in a range from 0.5 to 10 and particularly preferably in a range from 1 to 5.
- the parameter b is in this case in a range from 0.5 to 50 , preferably in a range of 1 to 10, and more preferably in a range of 2 to 5.
- the above-mentioned function (2) is understood as a function which is suitable for describing a corresponding amplitude curve, but describes the amplitude curve with respect to the illustrated function by means of other functions or functional components. These are in particular those functions which contain trigonometric functions such as sin x, cos x, aresin x or arecos x. These functions or subfunctions can replace individual components of the formula.
- Magnetic field amplitude within a main pulse as a function of x; x the time course; where x is again for each main pulse with the same
- the parameter a is in a range from 0.1 to 50, preferably in a range from 0.5 to 10 and particularly preferably in a range from 1 to 5.
- the parameter b is in this case in a range from 0.5 to 50 , preferably in a range of 1 to 10, and more preferably in a range of 2 to 5.
- the above-mentioned function (3) is understood as a function which is suitable for describing a corresponding amplitude curve, but describes the amplitude curve with respect to the illustrated function by means of other functions or functional components. These are in particular those functions which contain trigonometric functions such as sin x, cos x, aresin x or arecos x. These functions or subfunctions can replace individual components of the formula.
- the main pulses are superimposed by secondary pulses.
- the secondary pulses have a phase shift ⁇ with respect to the main pulses, which is between -0.45 ⁇ ⁇ 0.45, preferably between -0.40 ⁇ ⁇ 0.40.
- the phase shift ⁇ must be clear. A quasi-interference between the main and secondary pulses would only cause a higher amplitude.
- the secondary pulses according to the invention have the same frequency as adjacent main pulses. This has the advantage that the phase shift ⁇ between the main and secondary pulses for adjacent main and Mauimpulsfare remains constant.
- the envelope over main and secondary pulse thus has the same shape for adjacent main and Mauimpulspase. This ensures that the biological tissue experiences the same excitation for each individual main and secondary pulse pair by a sequence of main and secondary pulse pairs.
- the secondary pulses according to the invention have a frequency between 1 and 1000 Hz.
- the invention is designed in a further embodiment such that the amplitude of the secondary pulses is multiplied according to the invention by a factor which is between 0.1 times and 10 times the amplitude of the main pulses adjacent to the secondary pulses.
- the factor of the amplitude change is constant in a further embodiment of the invention for all adjacent secondary and main pulses, and that according to the invention in a time interval less than 1 s. This has the consequence that the resulting from the superposition of the two individual pulses form of adjacent main and Mauimpulszipen is the same.
- An impingement with pulse trains according to the invention leads to an effective excitation of the applied biological material only by the repetition of similar single pulses.
- the factor of the decreases in the amplitude of the secondary pulses according to the invention is equal to the factor of decreases in the amplitude of the main pulses, if the reduction of the main pulses within a time interval of a maximum of 3 s is at least 30% of the maximum amplitude of the main pulses.
- the individual admission intervals are interrupted by pauses in which the amplitude of the pulses is significantly lowered. To ensure that the main and secondary impulses are lowered evenly.
- the secondary pulses are generated in a further embodiment of the invention in the same time interval as the main pulses. Since the secondary pulses lead to significant effects only in combination with the corresponding main pulses, it is advantageous to generate main and secondary pulses in the same time interval.
- This time interval, in which the secondary and main pulses are generated, in a further embodiment of the invention is greater than 10 s. According to the invention, the time interval is preferably between 40 s and 120 s, more preferably between 70 s and 90 s. In a further embodiment of the invention, the time interval in which the secondary pulses are generated, according to the invention at least 10% of the time interval in which the main pulses are generated.
- the minimum duration for the main and sub impulse loading should be at least 10 s or 10% of the duration of the time interval at which the main impulses are generated.
- the frequency of the sub-pulses remains unchanged when the frequency of the main pulses changes.
- the frequency of the secondary pulses in a further embodiment of the invention is the same as that Start frequency of the main pulses.
- the phase shift ⁇ between at least part of the main pulses and secondary pulses in the second frequency range of the main pulses is equal to the phase shift ⁇ between main pulses and secondary pulses in the first frequency range.
- both the phase shift ⁇ and the frequency of the secondary pulses in a change in the amplitude of the individual pulses of adjacent individual pulses according to the invention are constant by a factor of less than 0.7 or greater 1.5.
- significantly altered single pulses in amplitude have a positive effect on the healing effect of exposure to an electric or electromagnetic field.
- the secondary pulse In order to obtain the improved excitation of the biological tissue achieved by the secondary pulses, even in the case of the individual pulses significantly changed in amplitude, the secondary pulse must continue to run unchanged. Therefore, the frequency of the sub-pulses remains constant with a significant change in the amplitude of a single pulse to an adjacent single pulse.
- a significant change in the amplitude of a single pulse occurs when the amplitude to an adjacent single pulse is smaller by at least a factor of 0.7, or larger by a factor of 1.5, than the adjacent single pulse.
- the ratio of the amplitude of the secondary pulses to the amplitude of the main pulses in a change in the amplitude of the individual pulses of adjacent individual pulses according to the invention is constant by a factor of less than 0.7 or greater 1.5.
- the secondary pulse In order to obtain the improved excitation of the biological tissue achieved by the secondary pulses, even in the case of the individual pulses significantly changed in amplitude, the secondary pulse must continue to run unchanged. Therefore, the amplitude of the sub-pulses remains constant with a significant change in the amplitude of a single pulse to an adjacent single pulse.
- a significant change in the amplitude of a single pulse occurs when the amplitude to an adjacent single pulse is smaller by at least a factor of 0.7, or larger by a factor of 1.5, than the adjacent single pulse.
- the secondary pulses have a compressed form in a further embodiment of the invention in comparison to the main pulses.
- sensors may be used which measure one or more different body parameters to optimize excitation of the body by the electromagnetic pulses.
- the sensors for example, blood pressure, temperature, pulse or respiratory volume can be detected and used to optimize the parameters of the device for generating electromagnetic radiation.
- Fig. 5 main pulses interrupted by a pause with constant amplitude
- the device according to the invention comprises at least one pulse generator 1 which generates a pulsating magnetic field in the coil 2.
- the field interacts with the living tissue 3, in particular a body of a patient to be treated.
- the device according to the invention comprises a sensor with which body parameters such as, for example, the temperature, the blood pressure, the pulse rate or the oxygen content of the blood can be detected. Via the feedback line 5, the detected body parameters are sent to a control unit 6 Posted.
- the controller 6 may also automatically set the optimal values for the parameters a to d and k, respectively.
- the effect of the pulsating magnetic field on the body to be treated can be detected and set as a function of various parameters of the pulsating magnetic field.
- parameters include, for example, the frequency of single, major, minor and / or sub-pulses or the amplitude of these pulses.
- the control unit determines the proportion transferred to the treated body. Via the control unit, the parameters of the pulsating magnetic field (a to d and k) can be adapted and optimized with regard to the treatment effect.
- the magnetic field has a sequence of main pulses 1 1, whose course in terms of amplitude and time in principle corresponds to the course shown in Fig. 2 b.
- FIG. 2 c shows a simplified form of the amplitude characteristic. The shape of the amplitude curves depends on the parameters a to d.
- Each main pulse 1 1 is in this case composed of a sequence of sub-pulses 13. The maximum intensities of these sub-pulses 13 increase in the course of a main pulse 1 1 at.
- the optimal shape of the sequence of sub-pulses 13 is individually very different. It depends on the type of tissue applied by the field, on the desired healing success and on the respective individual.
- the duty cycle between rest time and active pulse time can vary between 3: 1 to 1: 3, preferably it is approximately 1: 1. They are, for example, in the order of 0 to 200 ms.
- the duty cycle between idle time (times ta to tb) and pulse repetition time T is preferably between 0% and 300%. In some cases, however, the rest is unnecessary.
- Fig. 3 now main 1 1 and secondary pulses 12 and resulting from them resulting individual pulses 10 are shown for different phase shifts ⁇ .
- the figures show that with the secondary pulses 12 an important Instrument provided is the characteristic design of the resulting individual pulses 10 to influence significantly in order to achieve an optimized treatment success. While the total amplitude of the resulting pulses in FIGS.
- the amplitude characteristics of the resulting individual pulses 10 show clear differences.
- the number of the sum of the maxima of the resulting single pulse 10 and the difference in amplitude between the maximum and adjacent minimum of the resulting single pulse 10 or the slope of the flanks between the maximum and adjacent minimum can be varied. This ensures that the tissue can be addressed very individually with regard to the application and the relaxation.
- Main pulse 1 1 and secondary pulse 13 need not necessarily have the same amplitude.
- the duration of the resting phase t2 is preferably over 0.5 s, more preferably over 2 s. During these periods of rest, the maximum amplitude of the individual pulses is lowered to less than or equal to 30%. A reduction to 0 is also possible. In this resting phase, the treated tissue is given the opportunity for regeneration and relaxation.
- FIG. 6 shows a further exemplary embodiment in which the sequence of the resulting individual pulses 10 is subdivided into two time intervals.
- the amplitudes of lower 1 1 and secondary pulse 12 are approximately in a ratio of 3: 1.
- both the amplitude of the sub-pulse 1 1 and the amplitude of the sub-pulse 12 are lowered by 60%, but the amplitude ratio between the amplitude of the sub-pulse and the amplitude of the sub-pulse 12 remains.
- only the amplitude of the sub-pulse 12 is lowered.
- FIG. 7 shows an embodiment of the invention similar to the exemplary embodiment according to FIG. 6.
- the first and the second interval is interrupted by a resting phase 13.
- This resting phase 13 is a period of several resulting individual pulses 10. In this example, it is 10.
- FIG. 8 again shows a sequence of resulting individual pulses 10 in two successive time intervals.
- sub-pulse and sub-pulse have the same frequency and a constant phase shift ⁇ over the entire time period.
- the frequency of the sub-pulse and the sub-pulse is reduced by a factor of 0.5 in the second time interval.
- This dynamic adaptation takes place in this exemplary embodiment in order to take into account the changes in the tissue already occurring due to the application of magnetic pulses in the time interval 1.
- main pulse 1 1 and secondary pulse 12 with 8 Hz have the same frequency.
- the maximum amplitude of main 1 1 and secondary pulse 12 is constant.
- the maximum amplitude of the secondary pulse 12 is in this interval at 20% of the maximum amplitude of the main pulse 1 1.
- the phase shift ⁇ between secondary pulse 12 and main pulse 1 1 is -0, 1.
- the maximum amplitudes of main pulse 1 1 and lower Side pulse 12 by a factor of 0.05 in comparison to the maximum amplitudes of the first time interval from.
- the phase shift ⁇ remains constant.
- the second time interval is 15 s, of which the secondary pulse is sent in the first 1.5 s.
- the main pulse frequency of the 20 Hz and 25 Hz is that of the secondary pulse 12.
- the main 1 1 and secondary pulse 12 In a first time interval of 75 s, the main 1 1 and secondary pulse 12 have a constant maximum amplitude.
- the maximum amplitude of the secondary pulse 12 is a factor of 1, 5 higher value than the maximum amplitude of the main pulse 1 1.
- the phase shift ⁇ between secondary pulse and main pulse 1 1 is 0.05.
- the maximum amplitudes of main pulse 1 1 and secondary pulse 12 decrease by a factor of 0.1 compared to the maximum amplitudes of the first time interval.
- the phase shift ⁇ remains constant.
- the sub-pulse 12 In the first 21 seconds of the second time interval, the sub-pulse 12 is transmitted.
- the main pulse frequency and that of the secondary pulse 12 are each 37 Hz.
- main 1 1 and secondary pulse 12 have a constant maximum amplitude.
- the maximum amplitude of the main pulse 1 1 is a value higher by a factor of 0, 125 than the maximum amplitude of the secondary pulse 12.
- the phase shift ⁇ between secondary pulse and main pulse is 0.42.
- the maximum amplitudes of main pulse 1 1 and secondary pulse 12 decrease by a factor of 0.28 in comparison to the maximum amplitudes of the first time interval.
- the phase shift ⁇ remains constant.
- the frequency of the secondary pulse 12 decreases in the second time interval to 12 Hz.
- the optimal shape and sequence of the resulting individual pulses 10 depends on the nature of the tissue acted upon by the field, on the desired healing success and on the individual, and is therefore individually very different. Of decisive importance in the stimulation of the exchange processes in the body tissue is probably the high proportion and steepness of the rising or falling flank sections caused by the multiplicity of superimposed sub-pulses 13 and sub-plane pulses 14.
- the course of each resulting individual pulse 10 can be adapted to the actual conditions in such a way that an optimal stimulation is achieved.
- the parameters a, b, c, d, k, an, bn, cn, dn, and kn are adjusted such that application and relaxation are in a ratio optimized for this tissue.
- sensors are used which measure one or more body parameters around the application environment in order to detect the excitation of the organism by the electromagnetic pulses.
- the sensors can be used to measure tissue parameters such as blood pressure, temperature, pulse, ph-value or respiratory volume and in the sense of an adaptive Adapting the stimulation to the sensitivity of the tissue to be stimulated to optimize the parameters of the device for generating electromagnetic fields use.
- the adaptation could be made dynamically during the treatment in order to take account of short-term changes in the body condition and to further optimize the treatment success. This is done via a feedback loop that can compensate for the sensory changes in the applied tissue caused by the excitation itself.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Magnetic Treatment Devices (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102016122689.0A DE102016122689A1 (de) | 2016-11-24 | 2016-11-24 | Vorrichtung zur Beeinflussung biologischer Abläufe in einem lebenden Gewebe |
PCT/EP2017/068503 WO2018095590A1 (de) | 2016-11-24 | 2017-07-21 | Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebe |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3544676A1 true EP3544676A1 (de) | 2019-10-02 |
Family
ID=59593028
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17751656.4A Withdrawn EP3544676A1 (de) | 2016-11-24 | 2017-07-21 | Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebe |
Country Status (7)
Country | Link |
---|---|
US (1) | US11147981B2 (de) |
EP (1) | EP3544676A1 (de) |
KR (1) | KR20200022368A (de) |
CN (1) | CN110505899A (de) |
CA (1) | CA3023205A1 (de) |
DE (2) | DE202016008331U1 (de) |
WO (1) | WO2018095590A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102018101394A1 (de) | 2018-01-23 | 2019-07-25 | Prof. Dr. Fischer AG | Magnetfeldapplikator mit einem rampenförmigen Signalverlauf der verwendeten Spulenströme |
DE102020117033B3 (de) * | 2020-06-29 | 2021-09-16 | Centropix Global Ag | Vorrichtung zur Magnetfeldtherapie |
DE102021101671A1 (de) | 2021-01-26 | 2022-07-28 | Centropix Global Ag | Vorrichtung zur Magnetfeldtherapie |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US428366A (en) | 1890-05-20 | Steering apparatus | ||
US3895639A (en) * | 1971-09-07 | 1975-07-22 | Rodler Ing Hans | Apparatus for producing an interference signal at a selected location |
US4428366A (en) | 1981-05-06 | 1984-01-31 | Alfred B. Kurtz | Electromagnetic apparatus and method for the reduction of serum glucose levels |
DE3633493A1 (de) | 1986-10-02 | 1988-04-14 | Metallgesellschaft Ag | Verfahren zur katalytischen reduktion von no |
GB8624227D0 (en) | 1986-10-09 | 1986-11-12 | Therafield Holdings Ltd | Electrotherapeutic apparatus |
EP0293068A1 (de) * | 1987-05-27 | 1988-11-30 | Teijin Limited | Elektrotherapeutisches Gerät |
CA2003577C (en) | 1988-12-01 | 2001-04-17 | Abraham R. Liboff | Method and apparatus for regulating transmembrane ion movement |
CA2006319C (en) * | 1989-11-24 | 1995-01-24 | Dragon Susic | Magnetic massage therapy device |
US5181902A (en) | 1990-09-21 | 1993-01-26 | American Medical Electronics, Inc. | Double-transducer system for PEMF Therapy |
DE4221739A1 (de) | 1991-07-09 | 1993-01-14 | Fischer Ag | Vorrichtung zum transport von ionen, insbesondere protonen |
RU2017509C1 (ru) * | 1991-10-18 | 1994-08-15 | Тимченко Юрий Григорьевич | Магнитотерапевтический аппарат |
DE4335102A1 (de) | 1993-10-14 | 1995-04-20 | Fischer Ag | Einrichtung zur Ermittlung der Wirkung gepulster Magnetfelder auf einen Organismus |
CA2218060A1 (en) | 1995-04-13 | 1996-10-17 | Phoenix Safety Systems Limited | Mask |
DK0995463T3 (da) | 1998-10-21 | 2001-11-12 | Wolf A Prof Kafka | Anordning og elektrisk eller elektromagnetisk signal til påvirkning af biologiske processer |
ES2206025B1 (es) | 2002-05-21 | 2005-07-16 | Antonio Madroñero De La Cal | Dispositivo de campos magneticos multiples para su utilizacion en magnetoterapia y magneto acupuntura. |
ATE512695T1 (de) | 2007-10-17 | 2011-07-15 | Kafka Wolf A Prof Dr | Vorrichtung zur magnetfeldtherapie |
WO2011023634A1 (de) * | 2009-08-25 | 2011-03-03 | Peter Gleim | Vorrichtung zur stimulierung autoregulativer mechanismen der homöostase des organismus |
DE202012100245U1 (de) * | 2012-01-24 | 2012-04-27 | Apm-Wellness-Systems | Vorrichtung zur Erzeugung von Magnetfeldern für die Magnetfeldtherapie |
-
2016
- 2016-11-24 DE DE202016008331.8U patent/DE202016008331U1/de active Active
- 2016-11-24 DE DE102016122689.0A patent/DE102016122689A1/de not_active Withdrawn
-
2017
- 2017-07-21 CA CA3023205A patent/CA3023205A1/en not_active Abandoned
- 2017-07-21 CN CN201780072733.8A patent/CN110505899A/zh active Pending
- 2017-07-21 US US16/463,672 patent/US11147981B2/en active Active
- 2017-07-21 KR KR1020197013892A patent/KR20200022368A/ko unknown
- 2017-07-21 WO PCT/EP2017/068503 patent/WO2018095590A1/de unknown
- 2017-07-21 EP EP17751656.4A patent/EP3544676A1/de not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA3023205A1 (en) | 2018-05-31 |
WO2018095590A1 (de) | 2018-05-31 |
DE202016008331U1 (de) | 2017-09-04 |
DE102016122689A1 (de) | 2018-05-24 |
CN110505899A (zh) | 2019-11-26 |
US11147981B2 (en) | 2021-10-19 |
US20210113847A1 (en) | 2021-04-22 |
KR20200022368A (ko) | 2020-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2050481B1 (de) | Vorrichtung zur Magnetfeldtherapie | |
DE2748780C2 (de) | Vorrichtung zum Behandeln von lebenden Geweben und/oder Zellen mittels Impulsen entgegengesetzter Polarität | |
EP3544675A1 (de) | Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebe | |
DE69928383T2 (de) | Gerät zur steuerung der generierung elektrischer felder | |
DE10237519A1 (de) | Magnetfeldtherapie | |
EP3513836A2 (de) | Magnetfeldapplikator mit einem rampenförmigen signalverlauf der verwendeten spulenströme | |
DE2314573A1 (de) | Geraet zur foerderung von heilungsprozessen | |
DE202009013768U1 (de) | Sitz- oder Liegevorrichtung mit integrierter Schaltung zur Magnetfeldtherapie | |
EP0500983A1 (de) | Bestrahlungsvorrichtung zur Behandlung von lebendem Gewebe mit elektromagnetischen Wellen | |
EP3544676A1 (de) | Vorrichtung zur beeinflussung biologischer abläufe in einem lebenden gewebe | |
DE102017108084A1 (de) | Pulsquelle und Verfahren für die magnetisch induktive Nervenreizung | |
EP0995463A1 (de) | Vorrichtung und elektrisches oder elektromagnetisches Signal zur Beeinflussung biologischer Abläufe | |
DE3327920A1 (de) | Elektromagnetische therapeutische vorrichtung | |
DE2116869A1 (de) | Elektrisches Gerät zur Förderung der Neubildung von Knochen- und Gewebesubstanz | |
DE602004011187T2 (de) | Gerät zur elektrostimulation und für relative datenunterstützung | |
EP2506924B1 (de) | Vorrichtung zur elektrotherapeutischen behandlung | |
DE1239089B (de) | Verfahren zur Erhoehung der Absorptionsfaehigkeit von Kollagenerzeugnissen im lebenden Koerper | |
DE102020117033B3 (de) | Vorrichtung zur Magnetfeldtherapie | |
EP0332086A1 (de) | Betteil | |
DE102021101671A1 (de) | Vorrichtung zur Magnetfeldtherapie | |
Münch et al. | Sleep and circadian rhythms in ageing | |
WO2019007912A1 (de) | Verfahren zur einstellung eines gerätes zur behandlung mit kernspinresonanzen | |
DE102004024655A1 (de) | Arbeitsverfahren zum Betreiben einer Vorrichtung zur Probanden-Stimulation mittels zeitveränderlicher Mikroströme und/oder Magnetfelder und/oder Licht sowie zugehörige Vorrichtung | |
DE19904383C2 (de) | Verfahren zum Reizen einer einem Pathologiegebiet zugeordneten Reflexzone sowie Vorrichtung zum Durchführen des Verfahrens | |
Rosen et al. | Interdisziplinäres Gespräch: Analer Sphinkterersatz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20180118 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200507 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20200918 |
|
18RA | Request filed for re-establishment of rights before grant |
Effective date: 20210607 |